Drug Overview

Camrelizumab is an innovative, highly advanced cancer treatment that belongs to a powerful class of medicines known as Immunotherapy. Unlike traditional chemotherapy, which attacks all fast-growing cells in the body, camrelizumab works as a “Smart Drug.” It is designed to work with your body’s natural defenses, helping your own immune system recognize, attack, and destroy cancer cells.

While it has achieved widespread approval and use in some international markets (such as China), it is currently under active review by the United States Food and Drug Administration (FDA) and is primarily available in the US and Europe through clinical trials or specialized research programs.

Generic Name: Camrelizumab
US Brand Names: None (Currently an Investigational Agent in the US; marketed as AiRuiKa internationally)
Drug Class: PD-1 Checkpoint Inhibitor / Monoclonal Antibody (Immunotherapy)
Route of Administration: Intravenous (IV) Infusion (delivered directly into a vein)
FDA Approval Status: Investigational. (It is not yet fully FDA-approved for commercial sale in the US, though it has been submitted for review for certain liver cancers).

What Is It and How Does It Work? (Mechanism of Action)

Camrelizumab is a type of Immunotherapy called an immune checkpoint inhibitor. To understand how it works, we must look at how the immune system protects the body.

Your immune system has “soldier” cells called T-cells that patrol the body looking for infections and diseases, including cancer. To prevent these T-cells from accidentally attacking healthy parts of your body, they have built-in “brakes” or switches. One of the most important brake switches on a T-cell is called PD-1 (Programmed Cell Death protein 1).

Cancer cells are very clever and use this brake system to hide. They produce a protein on their surface called PD-L1. When the cancer cell’s PD-L1 connects with the T-cell’s PD-1 switch, it turns the immune cell “off.” The cancer cell essentially tells the immune system, “Leave me alone, I am a healthy cell.”

At the molecular level, camrelizumab is a laboratory-made antibody designed to block this exact interaction.

Blocking the Switch: The drug physically attaches itself to the PD-1 switch on the T-cell.
Removing the Brakes: Because the switch is covered, the cancer cell can no longer connect its PD-L1 protein to it.
Attacking the Tumor: With the “brakes” permanently removed, the T-cells remain active. They can now clearly recognize the tumor as a threat and attack the cancer cells, destroying them naturally.

FDA Approved Clinical Indications

Because camrelizumab is still under FDA review, it does not currently have official FDA-approved indications in the United States. However, it is heavily researched and internationally approved for several specific cancers.

Oncological Uses (Investigational in the US / Approved Internationally)

Hepatocellular Carcinoma (HCC) – the most common type of liver cancer.
Esophageal Squamous Cell Carcinoma (ESCC) – a type of throat/esophageal cancer.
Non-Small Cell Lung Cancer (NSCLC) – specifically in combination with chemotherapy.
Relapsed or Refractory Classic Hodgkin Lymphoma.
Nasopharyngeal Carcinoma.

Non-oncological Uses

There are no known, researched, or approved non-oncological uses for this drug. It is exclusively a cancer treatment.

Dosage and Administration Protocols

Because it is given directly into the bloodstream, camrelizumab must be administered in a hospital or specialized infusion clinic by a trained healthcare professional.

Patient Group	Standard Dose	Frequency	Administration Notes
Adults (Liver, Lung, Esophageal Cancers)	200 mg	Once every 2 weeks or 3 weeks (depending on protocol)	Administered as an IV infusion over 30 to 60 minutes.
Patients with Mild Renal/Hepatic Insufficiency	200 mg	Standard schedule	No starting dose adjustment is typically needed for mild impairment.
Patients with Severe Hepatic Insufficiency	Drug Withheld	N/A	If liver enzymes spike dangerously due to immune reactions, the drug is paused or permanently stopped.

Note: The exact schedule depends on whether the drug is given by itself or combined with other chemotherapy or targeted pills.

Clinical Efficacy and Research Results

Recent clinical trial data (spanning 2020 to 2024) has shown remarkable results, particularly for patients with advanced liver and esophageal cancers.

Liver Cancer (HCC): In a major global trial known as CARES-310 (published in 2023), researchers combined camrelizumab with a targeted pill called rivoceranib. The combination showed an impressive median Overall Survival (OS) rate of 22.1 months, compared to only 15.2 months for patients taking the older standard drug (sorafenib). This was a record-breaking survival time for advanced liver cancer trials.
Esophageal Cancer: In the ESCORT-1st trial, giving camrelizumab along with standard chemotherapy significantly extended both the time patients lived without the disease growing (progression-free survival) and their overall lifespan, reducing the risk of death by nearly 30% compared to chemotherapy alone.
Hodgkin Lymphoma: In heavily pre-treated patients who had run out of options, camrelizumab showed an Objective Response Rate (tumors shrinking significantly) of over 75%.

Safety Profile and Side Effects

Because Immunotherapy turns up the body’s immune system, it can sometimes cause the immune cells to become overly aggressive and attack healthy, normal organs.

Note: Because it is not FDA-approved yet, it does not carry a formal FDA “Black Box Warning,” but all drugs in this class carry severe warnings for immune-mediated organ damage.

Common Side Effects (>10%)

Reactive Capillary Hemangiomas: This is a very unique side effect specific to camrelizumab. About 60% to 70% of patients develop tiny, harmless, red “cherry-like” blood vessel bumps on the skin. They usually disappear when treatment stops.
Fatigue: Feeling unusually tired or weak.
Thyroid Dysfunction: The thyroid gland may become underactive (hypothyroidism) or overactive (hyperthyroidism).
Mild Rash and Itching
Gastrointestinal Upset: Mild diarrhea or nausea.

Serious Adverse Events

Immune-Mediated Pneumonitis: Severe inflammation of the lungs causing coughing and shortness of breath.
Immune-Mediated Hepatitis: Inflammation of the liver, shown by elevated liver enzymes and yellowing of the skin/eyes (jaundice).
Immune-Mediated Colitis: Severe inflammation of the intestines causing dangerous, watery diarrhea and stomach pain.

Management Strategies

For Immune Reactions: If a patient develops severe lung, liver, or bowel inflammation, the doctor will stop the immunotherapy and prescribe strong corticosteroids (like prednisone) to immediately calm the immune system down.
For Skin Hemangiomas: These are usually painless and only cosmetic. Doctors generally recommend observation, though severe ones can be treated with laser therapy.
For Thyroid Issues: Patients may need to take a daily thyroid hormone replacement pill.

Research Areas

Camrelizumab is currently a massive focus in combination therapy research. Tumors often build a blood-vessel “shield” around themselves that makes it hard for immune cells to get inside. Researchers are actively combining camrelizumab with specific anti-angiogenesis drugs (pills that cut off the tumor’s blood supply). This combination seems to normalize the blood vessels around the tumor, making it much easier for the T-cells activated by the immunotherapy to flood in and destroy the cancer. This synergistic approach is reshaping how doctors plan to treat aggressive digestive and liver cancers in the future.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Before starting this treatment, your healthcare team will need to perform:

Thyroid Panel (TSH/Free T4): To ensure your thyroid is functioning normally.
Comprehensive Metabolic Panel (CMP): To thoroughly check your liver and kidney health.
Complete Blood Count (CBC): To ensure your blood levels are safe for therapy.

Precautions During Treatment

Skin Care: Because the red skin bumps (hemangiomas) are common, avoid picking, scratching, or rubbing them, as they can bleed easily. Use soft towels and gentle soaps.
Symptom Awareness: Immune side effects can happen at any time—even months after you finish treatment.

“Do’s and Don’ts” list

DO call your doctor immediately if you develop a new, dry cough, chest pain, or trouble breathing.
DO report any severe diarrhea (more than 4 bowel movements a day over your normal habit) or severe stomach pain right away.
DO keep all appointments for your routine blood tests.
DON’T start any new prescription medicines, herbal supplements, or over-the-counter drugs without asking your oncologist first.
DON’T ignore extreme fatigue, sudden weight gain, or feeling unusually cold, as these can be signs that your thyroid has stopped working properly.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Camrelizumab is currently an investigational product in certain regions, and its approval status varies internationally. Treatment protocols, dosages, and side effects vary by individual and specific clinical guidelines. Patients should always consult with their primary oncologist or a qualified healthcare professional regarding diagnosis, treatment options, and the management of medical conditions. Do not disregard professional medical advice or delay in seeking it because of something you have read in this material.